Adults 18 to 99, any sex, with Psoriasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 16Primary· Week 16
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
Group
Value
95% CI
Placebo
7.1
CNTO1959 5 mg
34.1
CNTO1959 15 mg
61.0
CNTO1959 50 mg
78.6
CNTO1959 100 mg
85.7
CNTO1959 200 mg
83.3
Adalimumab
58.1
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16Secondary· Week 16
The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) t
Group
Value
95% CI
Placebo
4.8
CNTO1959 5 mg
43.9
CNTO1959 15 mg
75.6
CNTO1959 50 mg
81.0
CNTO1959 100 mg
78.6
CNTO1959 200 mg
81.0
Adalimumab
69.8
Difference in Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) in CNTO1959 Groups Compared With Adalimumab Group at Week 16Secondary· Week 16
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
Group
Value
95% CI
CNTO1959 5 mg
34.1
CNTO1959 15 mg
61.0
CNTO1959 50 mg
78.6
CNTO1959 100 mg
85.7
CNTO1959 200 mg
83.3
Adalimumab
58.1
Percentage of Participants With Physician Global Assessment (PGA) Score of Cleared (0) or Minimal (1) at Week 40Secondary· Week 40
PGA of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. Lesions were graded as erythema \[0 (no evidence of plaque) to 5 (dusky to deep red coloration)\], induration \[0 (no plaque evaluation) to 5 (marked plaque evaluation)\] and scaling \[0 (no evidence of scaling) to 5 (severe; very thick tenacious scaling)\]. The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0= cleared; 1= minimal; 2= mild; 3= moderate; 4= marked and 5= severe).
Group
Value
95% CI
CNTO1959 5 mg
35.3
CNTO1959 15 mg
59.5
CNTO1959 50 mg
71.1
CNTO1959 100 mg
76.9
CNTO1959 200 mg
81.1
Adalimumab
48.6
Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16Secondary· Baseline and Week 16
The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scor
Group
Value
95% CI
Placebo
-2.3
± 6.80
CNTO1959 5 mg
-6.2
± 5.24
CNTO1959 15 mg
-10.3
± 5.49
CNTO1959 50 mg
-11.1
± 7.38
CNTO1959 100 mg
-10.8
± 7.34
CNTO1959 200 mg
-11.4
± 6.83
Adalimumab
-10.1
± 9.00
Adverse events — posted to ClinicalTrials.gov
Time frame: Baseline (Week 0) up to Week 52.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
NCT07471048 — A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoria
· NA
· recruiting
NCT07449234 — A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
· recruiting
NCT07234838 — Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
· recruiting
NCT07194200 — Safety and Efficacy of Lactobacillus Plantarum for Psoriasis: A Randomized Double-Blind Placebo-Controlled Trial
· Phase 2
· recruiting
NCT07250997 — PALLAS Laser for Skin Diseases
· NA
· recruiting
Other Janssen Inc. trials
Trials by the same sponsor.
NCT03729349 — Golimumab for Adherence in Rheumatoid Arthritis
· completed
NCT03501173 — A Study of Participants With Advanced Prostate Cancer in Canada
· completed
NCT02688075 — An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in
· completed
NCT02364531 — A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Sett
· completed
NCT00741793 — Biologic Treatment Registry Across Canada
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Inc.
Last refreshed: 2 August 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01483599.